Molecular structure of Bleomycin, CAS Number: 11056-06-7
Bleomycin (CAS 11056-06-7)
See product citations (5)
Alternate Names:
Bleo, Bleocin, BLM
CAS Number:
11056-06-7
Molecular Weight:
1415.55
Molecular Formula:
C55H84N17O21S3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bleomycin (CAS 11056-06-7) References
- Bleomycin: new perspectives on the mechanism of action. | Hecht, SM. 2000. J Nat Prod. 63: 158-68. PMID: 10650103
- Mouse models of bleomycin-induced pulmonary fibrosis. | Walters, DM. and Kleeberger, SR. 2008. Curr Protoc Pharmacol. Chapter 5: Unit 5.46. PMID: 22294226
- Complications of intralesional bleomycin in the treatment of orbital lymphatic malformations. | MacIntosh, PW., et al. 2014. Semin Ophthalmol. 29: 450-5. PMID: 25325873
- Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. | Della Latta, V., et al. 2015. Pharmacol Res. 97: 122-30. PMID: 25959210
- DNA and chromosome damage induced by bleomycin in mammalian cells: An update. | Bolzán, AD. and Bianchi, MS. 2018. Mutat Res Rev Mutat Res. 775: 51-62. PMID: 29555029
- The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA. | Murray, V., et al. 2018. Int J Mol Sci. 19: PMID: 29734689
- Converting bleomycin into a prodrug that undergoes spontaneous reactivation under physiological conditions. | Cooper, I., et al. 2019. Toxicol Appl Pharmacol. 384: 114782. PMID: 31655077
- HSP70 induction by bleomycin metal core analogs. | Ali, TFS., et al. 2020. Bioorg Med Chem Lett. 30: 127002. PMID: 32044184
- Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis. | Chin, C., et al. 2023. Cell Rep Med. 4: 100945. PMID: 36787736
- Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report. | Muir, T., et al. 2023. Radiol Oncol. 57: 141-149. PMID: 37341196
Inhibitor of:
α-Dystrobrevin, 4921530L21Rik, 4930432K21Rik, ARV1, B930041F14Rik, BC117090, BXDC1, C10orf28, C11orf91, CAS4, CIZ1, COL4A6, COL5A3, CrxOS, Cytokeratin 15, DCAR, DCAR1, Dclre1c, DDX37, DDX42, DDX52, Dematin, DNA pol ε B, DNAHC7B, ds DNA Marker, EG232801, ETAA16, FAM137B, FAM139A, Gm1862, Gm8994, GNL2, gp210, Hairy, HBXIP, hCAP-D2, HEI10, HEL308, HN1L, Hop2, ITFG3, KIN17, KLH-A, Lamin B2, Laminin-5, LFY, LOH12CR1, LRG1, Mec3, MMS19, MND1, MRT-2, MUP18, Ncapd3, Nop5, NTH1, OBFC2B, OFCC1, Olr203, OTTMUSG00000016783, pescadillo, PGBD1, Phakinin, PIF1, Placental RNase inhibitor, PMS2, POLDIP2, PRIM2A, PSG20, Rad55, RBM10, RBM42, RecA, RFC, RWDD2A, Separase, Sgs1, SMC2, SMC5, SNM1B, SPAG11B, ss DNA marker, SSBP1, SSNA1, Sycp2l, TFIIH p8, Titin, Tns3, TRAG-3, TRIP, Tropomyosin β, Ubr4, VCY1B, XPG, XRRA1, ZBTB8B, ZFF29, ZFP108, ZFP109, ZFP192, ZFP213, ZFP26, and ZNF207.Activator of:
53BP1, AMAP-1, APLF, AROS-29, Atm, BC055324, BRAF35, Bub2, C230052I12Rik, Cdc13, Cdc25C, Cdt2, Chk1, Cid, cyclin A-type, D19Bwg1357e, DCC1, Dclre1c, DDI1, DDX15, Dmc1, DNA pol ε A, DNA pol ι, DNA-PKCS, Dun1, Elm1, EndoV, ESCO2, Esp1, FAM128A, FHAD1, Fibroblast Marker, FLJ20433, GEN1, GTSE-1, Haspin, hCAP-G, HPF1, Hus1B, Kar9, KIAA0406, Ku, Ku-86, MCM5, MCM9, MDC1, MEI1, MKLP-1, MRE11_Mre11, MUS81, ncd, NSE2, OIP5, p107, PARP-8, Pericentrin 2, PGBD5, POLA2, Rad26L, Rad5, RAD51AP1, Rad51B, Rad51D, Rad52, Rad53, Rad57, Rad59, Rad9, Rad9B, Ras GAP, RBM35A, Ribosomal Protein L10a, RNF113B, RNF169, RRP22, RuvA, SNM1B, SPHAR, Spo11, Spo12, Srs2, TAZ, TFIIH p89, WDR57, Wee 1, XRCC4, and ZNF668.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bleomycin, 5 mg | sc-507293 | 5 mg | $270.00 |